Some cancers evade targeted therapies through a mechanism known as lineage plasticity,
whereby tumor cells acquire phenotypic characteristics of a cell lineage whose survival no …

Prostate cancer relapsing from antiandrogen therapies can exhibit variant histology with
altered lineage marker expression, suggesting that lineage plasticity facilitates therapeutic …

Abstract Characterization of the prostate cancer transcriptome and genome has identified
chromosomal rearrangements and copy number gains and losses, including ETS gene …

Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or
acquired resistance to second-generation androgen-targeting therapies and minimal …

Despite advances in detection and therapy, castration-resistant prostate cancer continues to
be a major clinical problem. The aberrant activity of stem cell pathways, and their regulation …

Drug resistance in cancer is often linked to changes in tumor cell state or lineage, but the
molecular mechanisms driving this plasticity remain unclear. Using murine organoid and …

The androgen receptor (AR) is overexpressed and hyperactivated in human castration-
resistant prostate cancer (CRPC). However, the determinants of AR overexpression in …

Abstract Treatment of prostate cancer (PC) by androgen suppression promotes the
emergence of aggressive variants that are androgen receptor (AR) independent. Here we …

New strategies are needed to predict and overcome metastatic progression and therapy
resistance in prostate cancer. One potential clinical target is the stem cell transcription factor …

Androgen deprivation is the cornerstone of prostate cancer treatment. It results in involution
of the normal gland to~ 90% of its original size because of the loss of luminal cells. The …